Idelalisib is a chemotherapic medication used to treat blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, lymphoma, and non-Hodgkin's lymphoma. In the case of chronic lymphocytic leukemia, it is recommended as a second-line treatment and is typically used alongside rituximab. Suppliers of idelalisib market it as 100mg and 150mg oral tablets. First introduced for medical use in 2014 by developer and earliest idelalisib manufacturer Gilead Sciences, the drug has since become available in over 30 countries worldwide. Given that the patent for the drug is still valid, other producers have yet to join the market with their own generic or trade name formulations of idelalisib. Pharmaceutical specialists are welcome to browse through offers of idelalisib tablets from suppliers on our pharmaceutical marketplace, or else seek out further useful medical information about idelalisib online, at the official Zydelig product website.